Back to news

Merck Slips as Melanoma Vaccine Data Sparks a Sell-the-News Reaction

Investivoq PriceTracker

Merck & Co. (MRK) is down 3.2% today. Here is some analysis on what might have caused this price movement. ([finance.yahoo.com](https://finance.yahoo.com/markets/stocks/articles/market-chatter-moderna-merck-shares-173236624.html?utm_source=openai))

Analysis: The drop appears tied mainly to volatility around Merck and Moderna’s personalized melanoma vaccine program after Phase 3 results leaked early and were then fully released ahead of a major oncology presentation. The study showed the combination with Keytruda reduced the risk of recurrence or death, but the market reaction suggests investors had been positioned for an even stronger readout, creating a sell-the-news move rather than a fundamental blow to Merck’s business. ([apnews.com](https://apnews.com/article/415ececd79c9411498751246742aafa2?utm_source=openai))

Details:

  • Merck and Moderna said their Phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda cut the risk of melanoma recurrence or death by 42% versus Keytruda alone. ([apnews.com](https://apnews.com/article/415ececd79c9411498751246742aafa2?utm_source=openai))
  • Some of the trial data circulated publicly before the scheduled medical-meeting presentation, which appears to have accelerated trading volatility in both partner stocks. ([apnews.com](https://apnews.com/article/415ececd79c9411498751246742aafa2?utm_source=openai))
  • Merck had already highlighted the trial as a major ESMO 2026 event, so expectations were elevated going into the presentation and investor event. ([merck.com](https://www.merck.com/news/merck-showcases-first-time-pivotal-phase-3-results-from-oncology-pipeline-and-continued-innovative-potential-of-existing-portfolio-at-esmo-2026/?utm_source=openai))
  • Near-term sentiment may also be cautious because Merck is scheduled to report third-quarter 2026 results on October 29, 2026. ([merck.com](https://www.merck.com/news/merck-to-hold-third-quarter-2026-sales-and-earnings-conference-call-oct-29/?utm_source=openai))
  • Sources:

    Merck, Associated Press, Reuters ([merck.com](https://www.merck.com/news/merck-showcases-first-time-pivotal-phase-3-results-from-oncology-pipeline-and-continued-innovative-potential-of-existing-portfolio-at-esmo-2026/?utm_source=openai))

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $MRK Insider Trading Activity

    MRK Insider Trades

    $MRK insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

    Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

    • JENNIFER ZACHARY (EVP, General Counsel) sold 80,315 shares for an estimated $10,718,494
    • DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 3 sales selling 52,847 shares for an estimated $6,805,145.
    • RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) has made 0 purchases and 8 sales selling 51,370 shares for an estimated $6,731,142.
    • CHIRFI GUINDO (EVP, Access, Policy & Comms) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $3,315,000.
    • DAVID R. MARALDO (EVP & Pres. MMD) has made 0 purchases and 3 sales selling 18,706 shares for an estimated $2,407,797.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive MRK Data Alerts
    Get market-moving data, filings, and signals for MRK in real time.
    Sign Up

    $MRK Hedge Fund Activity

    We have seen 1,796 institutional investors add shares of $MRK stock to their portfolio, and 1,673 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 54,365,289 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,985,939,636
    • JPMORGAN CHASE & CO added 43,886,420 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,639,404,970
    • CAPITAL INTERNATIONAL INVESTORS added 14,516,428 shares (+1668.1%) to their portfolio in Q2 2026, for an estimated $1,865,360,998
    • FISHER ASSET MANAGEMENT, LLC added 12,079,979 shares (+45.7%) to their portfolio in Q2 2026, for an estimated $1,552,277,301
    • NORDEA INVESTMENT MANAGEMENT AB removed 5,024,243 shares (-58.9%) from their portfolio in Q2 2026, for an estimated $645,615,225
    • CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 4,600,064 shares (+9.2%) to their portfolio in Q2 2026, for an estimated $591,108,224
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 4,524,046 shares (-19.6%) from their portfolio in Q2 2026, for an estimated $581,339,911

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $MRK Government Contracts

    We have seen $3,577,363 of award payments to $MRK over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • ERVEBO PROCUREMENT: $190,468

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    $MRK Congressional Stock Trading

    Members of Congress have traded $MRK stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

    • REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 3 times. They made 2 purchases worth up to $100,000 on 08/19 and 1 sale worth up to $15,000 on 09/24.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $MRK Price Targets

    Multiple analysts have issued price targets for $MRK recently. We have seen 8 analysts offer price targets for $MRK in the last 6 months, with a median target of $139.5.

    Here are some recent targets:

    • Terence Flynn from Morgan Stanley set a target price of $113.0 on 07/09/2026
    • Mohit Bansal from Wells Fargo set a target price of $150.0 on 07/08/2026
    • Trung Huynh from RBC Capital set a target price of $142.0 on 07/08/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 07/06/2026
    • Louise Chen from Scotiabank set a target price of $155.0 on 06/30/2026
    • Tim Anderson from B of A Securities set a target price of $141.0 on 06/30/2026
    • An analyst from CICC set a target price of $138.0 on 06/24/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.